SCHEMBL4145437

SCHEMBL4145437

COc1ccc(N(c2ccccc2)C2CCCNC2)nc1OCC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.38
KCNH2 Q12809 3/20 0.36
SYK P43405 2/20 0.36
AURKB Q96GD4 2/20 0.36
IKBKB O14920 1/20 0.36
CHUK O15111 1/20 0.36
CDK9 P50750 2/20 0.35
KIT P10721 1/20 0.35
RPLP1 P05386 1/20 0.35
RPLP0 P05388 1/20 0.35
RPS17 P08708 1/20 0.35
RPSA P08865 1/20 0.35
RPS2 P15880 1/20 0.35
RPL35A P18077 1/20 0.35
RPL7 P18124 1/20 0.35
RPL17 P18621 1/20 0.35
RPS4Y1 P22090 1/20 0.35
RPS3 P23396 1/20 0.35
RPS12 P25398 1/20 0.35
RPL13 P26373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136073 0.76 SLC6A4 (0.35) CDK9SLC6A2SLC6A4SLC6A3CCNT1
SCHEMBL4131908 0.70 NR3C2 (0.37) KCNH2IKBKBSLC6A2SLC6A4SLC6A3
SCHEMBL2906305 0.67 CHRM2 (0.39) FFAR4IKBKBCHUKCHRNB4CHRNA3
SCHEMBL4136136 0.67 EP300 (0.39) FFAR4AURKBHTR4SLC6A2SLC6A4
SCHEMBL4134857 0.66 SLC6A2 (0.39) KCNH2SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL4139398 0.66 FGFR1 (0.37) SLC6A2SLC6A4SLC6A3
SCHEMBL8252669 0.65 MC4R (0.36) KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL1475538 0.65 CHRNB4 (0.61) IKBKBCHUKKITCHRNB4CHRNA3
SCHEMBL3325029 0.65 CHRNB4 (0.45) IKBKBCHUKKITACP1CHRNB4
SCHEMBL3325033 0.65 CHRNB4 (0.45) IKBKBCHUKKITACP1CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS TALAMAS FRANCISCO XAVIER 2009-05-07 US claimed
EP-1888528-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-02-20 EP claimed
US-20070049611-A1 Phosphodiesterase 4 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US claimed
WO-2006135828-A2 TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-12-21 WO claimed
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS TALAMAS FRANCISCO XAVIER 2009-05-07 US disclosed
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS TALAMAS FRANCISCO XAVIER 2009-05-07 US disclosed
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS TALAMAS FRANCISCO XAVIER 2009-05-07 US disclosed
EP-1888528-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-02-20 EP disclosed
US-20070049611-A1 Phosphodiesterase 4 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed
US-20070049611-A1 Phosphodiesterase 4 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed
US-20070049611-A1 Phosphodiesterase 4 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed
WO-2006135828-A2 TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049611-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE4B FFAR4 1248/4885KCNH2 236/4885SYK 3042/4885
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE4B FFAR4 1248/4885KCNH2 236/4885SYK 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.